AnaptysBio (ANAB) Earnings Date & Reports

Key Takeaways

• AnaptysBio reported net income of $183.9 million for the second quarter ended June 30, 2026, swinging from a net loss of $38.6 million a year earlier.
• The profit was driven largely by a one-time, non-cash $181.5 million income tax benefit, tied to the release of a valuation allowance on deferred tax assets.
• Collaboration revenue rose to $27.5 million, up from $22.3 million a year ago, boosted by a 25% year-over-year increase in Jemperli royalties.
• Diluted earnings per share from continuing operations reached $4.93, compared with $0.19 in the prior-year quarter.
• Cash, cash equivalents, and investments declined to $164.1 million from $211.6 million at the end of 2025.
• The company completed its separation from First Tracks Biotherapeutics and shifted its fiscal year-end to June 30, refocusing on royalty collaborations.

Earnings Context and Why It Matters

This quarterly earnings report marked a turning point for AnaptysBio, which has transformed from a clinical-stage drug developer into a royalty-focused company managing financial collaborations around two partnered therapies: Jemperli (dostarlimab) with GSK and Quimilza (imsidolimab) with Vanda. The quarter captured the first full reporting period after the April 20, 2026 separation from First Tracks Biotherapeutics, a structural change that reshaped both the income statement and the tax position. For investors, the report is less about the headline profit and more about the durability of the underlying royalty stream, cash runway, and the company's ability to convert partnered drug sales into recurring revenue.

Reported Results

AnaptysBio reported collaboration revenue of $27.5 million for the three months ended June 30, 2026, up from $22.3 million in the year-ago period and ahead of analyst expectations. The increase was driven by a 25% rise in Jemperli royalties, partially offset by the absence of $9.7 million in revenue recognized from the Vanda license agreement in the prior-year quarter. GSK reported Jemperli global net sales of $331 million for the quarter, up 26% year over year.

The company posted net income of $183.9 million, or $5.11 per diluted share, versus a net loss of $38.6 million, or $1.30 per share, a year earlier. Income from continuing operations was $177.3 million, or $4.93 per basic share. The swing was driven primarily by a $181.5 million benefit for income taxes, reflecting the release of a valuation allowance on deferred tax assets following the First Tracks Biotherapeutics separation.

General and administrative expenses rose to $16.0 million from $4.0 million, reflecting separation-related legal costs and non-cash stock compensation. Cash, cash equivalents, and investments totaled $164.1 million at quarter-end, down $47.5 million from December 31, 2025, as operating cash outflows were partially offset by stock option exercises.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like AnaptysBio (ANAB), it offers a practical way to monitor shifts in sentiment and technical momentum across the biotechnology sector.

Market Reaction and Investor Sentiment

Investor interpretation of AnaptysBio's results has centered on distinguishing the one-time tax benefit from the company's underlying operating performance. Because the $181.5 million tax benefit is non-cash and non-recurring, analysts and investors have largely looked through the headline profit to assess the health of the royalty business. The 25% growth in Jemperli royalties and the beat on collaboration revenue provided a more durable signal of commercial momentum, while the decline in cash reserves underscored ongoing cash burn as the company transitions to a leaner, royalty-driven model.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on several catalysts tied to AnaptysBio's partnered assets. Management expects an FDA decision on Jemperli as a monotherapy in dMMR/MSI-H (mismatch repair deficient/microsatellite instability-high) neoadjuvant rectal cancer within roughly six months, and a potential approval for Quimilza in generalized pustular psoriasis, or GPP, by December 2026.

The royalty trajectory also carries long-term weight. AnaptysBio continues to expect annualized Jemperli royalties payable to the company to exceed $390 million as early as 2029, based on GSK's peak monotherapy sales guidance of more than $2.7 billion. Near-term, investors should watch the outcome of ongoing litigation with GSK and Tesaro, which could affect the value and timing of those royalty economics.

Finally, the balance sheet remains a key monitor. The company has a $100 million stock repurchase plan in place that expires on December 31, 2026, and had not repurchased shares as of quarter-end. With cash of $164.1 million, the pace of operating cash use and any capital-return activity will shape how the market views the company's financial flexibility in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations